KR920002790A - 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신 - Google Patents

보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신 Download PDF

Info

Publication number
KR920002790A
KR920002790A KR1019910011724A KR910011724A KR920002790A KR 920002790 A KR920002790 A KR 920002790A KR 1019910011724 A KR1019910011724 A KR 1019910011724A KR 910011724 A KR910011724 A KR 910011724A KR 920002790 A KR920002790 A KR 920002790A
Authority
KR
South Korea
Prior art keywords
vaccine
pertussis
antigens
combined
outer membrane
Prior art date
Application number
KR1019910011724A
Other languages
English (en)
Inventor
지이 에크하아트 토마스
다불류 곳토 존
케이 맥클리토우크 데이빗
브이 스콧트 제인
Original Assignee
알퐁스 아아르 노에
아메리칸 사이아나밋드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24192174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR920002790(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 알퐁스 아아르 노에, 아메리칸 사이아나밋드 캄파니 filed Critical 알퐁스 아아르 노에
Publication of KR920002790A publication Critical patent/KR920002790A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

내용 없음

Description

보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한, 형성하기 위해 합해지기 전에 개별적으로 정제되어 백신을 백일해 항원들, 선상 혈구응집소(FHA), 무독화된 임파구증가 촉진인자(LPF) 및 69킬로달톤의 외막 단백질로 구성되는 백신.
  2. 제1항에 있어서, 항원들은 전세포 또는 공동-정제된 비세포성 백일해 백신에서는 가능하지 않은 비율을 포함하여, 임의의 바람직한 비유로 합해지는 백신.
  3. 제2항에 있어서, 항원들 ,FHA, LPF 및 69 킬로달톤의 외막 단백질은 4 : 2 : 1 비율로 합해지는 백신.
  4. 제1항에 있어서, 하나 이상의 하기 (a) 또는 (b)의 부가적 항원이 포함됨을 특징으로 하는 백신, (a) 백신을 형성하기 위해 다른 백일해 항원과 합해지기 저에 개별적으로 정제되는 보르데델라 퍼투스시스로 부터의 하나이상의 응집원, 또는 (b) 백신을 형성하기 위해 다른 백일해 항원과 합해지기 전에 개별적으로 정제되는 보르데델라 퍼투스시스로 부터의 30킬로탈톤의 외막 단백질.
  5. 제4항에 있어서, 응집원이 채(fimbriae)인 백신.
  6. 제1항에 있어서, 하나 이상의 생리학적으로 허용가능한 백일해 구조 성분이 포함되는 백신.
  7. 제6항에 있어서, 백일해 구조 성분은 폴리사카라이드, 리포폴리사카라이드, 지질 단백질, 당단백질 및 지방단백질로 구성되는 군으로 부터 선택되는 백신.
  8. 제6항에 있어서, 백일해 항원이 서로서로에 또는 백일해 구조성분에 콘쥬게이트되는 백신.
  9. 비백일해 백신 성분과 조합된 제1항의 백일해 백신으로 구성되는 다가성 백신.
  10. 제9항에 있어서, 비백일해 백신 성분은 하나 이상의 하기 (a) 또는 (b)의 부가적 항원인 백신, (a)실활된 소아마비 비루스, 헤모필로스 인플루엔자(Haemophilus influenzae),헤모필러스 폴리리보실 인산염-단백질 콘쥬게이트, 수막염균, 폐염구균 및 간염균 B, 또는 (b) 디프레리아 톡소이드 및 파상풍 톡소이드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910011724A 1990-07-11 1991-07-10 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신 KR920002790A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54923690A 1990-07-11 1990-07-11
US07/549,236 1990-07-11

Publications (1)

Publication Number Publication Date
KR920002790A true KR920002790A (ko) 1992-02-28

Family

ID=24192174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910011724A KR920002790A (ko) 1990-07-11 1991-07-10 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신

Country Status (10)

Country Link
US (4) US5895655A (ko)
EP (1) EP0484621A3 (ko)
JP (1) JPH04230328A (ko)
KR (1) KR920002790A (ko)
AU (1) AU8033591A (ko)
CA (1) CA2046543A1 (ko)
FI (1) FI913350A (ko)
IL (1) IL98233A0 (ko)
NO (1) NO912713L (ko)
PT (1) PT98257A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066608B2 (en) 2009-01-14 2015-06-30 Moon Hwan Park Nursing cushion

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
US5156958A (en) * 1990-09-21 1992-10-20 American Cyanamid Company Gene encoding a 30 kilodalton outer membrane protein of bordetella pertussis and method of recombinant production of said protein
US6444211B2 (en) * 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
ATE275970T1 (de) 1993-10-05 2004-10-15 Celltech Pharmaceuticals Ltd Impfstoffzusammensetzungen
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
EP1233022B1 (en) * 1995-05-04 2015-12-09 Aventis Pasteur Limited Methods of preparation of components of acellular pertussis vaccines
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
EP1762246A1 (en) * 1996-07-02 2007-03-14 Sanofi Pasteur Limited Multivalent DTP-Polio vaccines
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
JP2001085516A (ja) * 1999-09-10 2001-03-30 Oki Electric Ind Co Ltd 半導体装置の製造方法
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
FR2809960B1 (fr) * 2000-06-07 2004-04-23 Pasteur Institut Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
US20020051794A1 (en) * 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
EP1523279A2 (en) * 2002-04-09 2005-04-20 Neville Alleyne Bone fixation apparatus
WO2005032584A2 (en) 2003-10-02 2005-04-14 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US7578803B2 (en) * 2004-03-18 2009-08-25 C. R. Bard, Inc. Multifunction adaptor for an open-ended catheter
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
MX2007007288A (es) * 2004-12-17 2008-02-25 Nvi Nl Vaccininst Desacilacion de lps en bacterias gram negativas.
JP5207380B2 (ja) * 2006-03-27 2013-06-12 北里第一三共ワクチン株式会社 長期保存においても毒性復帰がおこらない特徴を持つ全菌体細菌ワクチンならびにその用途
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
DK2863943T3 (en) 2013-03-08 2016-11-07 Janssen Vaccines & Prevention Bv acellular pertussis vaccines
EP3454895B1 (en) 2016-05-10 2024-03-27 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3043291A1 (de) * 1980-11-17 1982-07-01 Dso Pharmachim Vakzine gegen keuchhusten
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
GB8412207D0 (en) * 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
FR2590483B1 (fr) * 1985-11-22 1988-12-09 Pasteur Institut Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
FR2597344B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire.
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
US5276142A (en) * 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066608B2 (en) 2009-01-14 2015-06-30 Moon Hwan Park Nursing cushion

Also Published As

Publication number Publication date
NO912713L (no) 1992-01-13
NO912713D0 (no) 1991-07-10
FI913350A (fi) 1992-01-12
CA2046543A1 (en) 1992-01-12
EP0484621A3 (en) 1992-08-26
AU8033591A (en) 1992-01-16
US5885586A (en) 1999-03-23
JPH04230328A (ja) 1992-08-19
IL98233A0 (en) 1992-06-21
US5895655A (en) 1999-04-20
EP0484621A2 (en) 1992-05-13
US5885587A (en) 1999-03-23
FI913350A0 (fi) 1991-07-10
PT98257A (pt) 1992-04-30
US5897867A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
KR920002790A (ko) 보르데텔라 퍼투스시스에 의해 발병되는 질병을 예방하는데 유효한 백신 및 비백일해 백신 성분과 조합된 상기 백신으로 구성되는 다가성 백신
UY26801A1 (es) Composición de vacuna
YU24391A (sh) Poboljšana meningokokna polisaharid kon-jugovana vakcina
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
LU91924I2 (fr) Composition vaccinale comprenant le polysaccharidecapsulaire et Haemophilus influenzae type b coupl é à l'anatoxine tétanique, l'antigène diphtérique,l'antigène tétanique, des antigènes de la polio, des antigènes de la coqueluche et du phosphate d'aluminium
BR9710460A (pt) Composi-Æo imunolÄgica multi-valente e seu uso em vacinas
DE69111168D1 (de) Verbesserte Vakzine auf der Basis von Oligosaccharid-Konjugaten.
ES2180758T3 (es) Vacunas de pertussis acelulares y metodos de preparacion de las mismas.
FI913820A0 (fi) Traodlikt hemagglutinin fraon bordetella pertussis som baerarmolekyl foer konjugatvaccin.
NO912369D0 (no) Meningokokk-klasse-1-ytre-membranvaksine.
ES2152421T3 (es) Vacunas de conjugados polisacarido neumococcico-neumolisina recombinante para la inmunizacion contra las infecciones neumococcicas.
DE69331495T2 (de) Impfstoffe gegen neisseria meningitidis gruppe c
ATE480257T1 (de) Kombinationsvakzine mit niedriger dosis eines hib-konjugats
DE69131709T2 (de) Liposomen enthaltende impfstoffzusammensetzungen
BRPI9712917B8 (pt) composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
EP0761230A3 (en) Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine
ES520915A0 (es) Procedimiento de preparacion de un conjugado de muramilpeptido y de un hapteno o fragmento haptenico de bajo peso molecular.
ATE105189T1 (de) Haemophilus influenzae typ b polysaccharidaussermembranprotein-konjugat als impfstoff.
ES8401722A1 (es) Procedimiento de obtencion de vacunas contra el patogeno h influenzae tipo b.
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
ES8502339A1 (es) Procedimiento de obtencion de una vacuna para ejercer la formacion de anticuerpo de fosfato de poliribosilribitol (prp) en un animal de sangre caliente

Legal Events

Date Code Title Description
WITB Written withdrawal of application